CJC-1295

synthetic

Also known as: CJC 1295, CJC1295

Growth Hormone Releasing Hormone AnalogsResearch phase: phase_2_humanRegulatory: research_only

Mechanism

CJC-1295 is a synthetic growth hormone releasing hormone (GHRH) analog that stimulates the pituitary gland to release growth hormone. Unlike natural GHRH which is quickly broken down in the body, CJC-1295 is modified to resist degradation, allowing it to work for days rather than minutes.

Technical detail

CJC-1295 is a 29-amino acid synthetic analog of GHRH (1-29) with four amino acid substitutions that increase binding affinity and resistance to DPP-IV enzymatic cleavage. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, activating the cAMP-PKA pathway to stimulate GH synthesis and secretion. The drug has an extended half-life of 5.8-8.1 days due to bioconjugation with serum albumin via a reactive maleimide group.

Evidence

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Ionescu M et al. (2006) — J Clin Endocrinol Metab — PMID: 17018654
Clinical trial in healthy men found single-dose CJC-1295 preserved pulsatile GH secretion while markedly increasing trough GH (~7.5-fold), mean GH (+46%), and IGF-1 (+45%) one week after dosing, supporting durable endocrine activity with intact pulsatility.
moderate

Build a personalized protocol with CJC-1295 →